A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Recruitment & Eligibility

Inclusion Criteria

Subject is a male or non-pregnant female 18 years of age or older.
Subject has provided written informed consent.
Females must be post-menopausal, surgically sterile, or use a highly effective method of birth control during the trial and for 30 days after the last administration of test article. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline.
Male subjects who are not surgically sterile (e.g., vasectomy performed at least 6 months prior to trial entry) and are sexually active with a female partner who is of childbearing potential must agree to use an effective form of birth control for the duration of the trial and for 90 days after completion of treatment.
Subject, in the investigator's opinion, is in good general health and free of any disease state or physical condition that might impair evaluation of plaque psoriasis or exposes the subject to an unacceptable risk by trial participation.

Exclusion Criteria

Subject is pregnant, lactating, or is planning to become pregnant during the trial.
Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis or which exposes the subject to an unacceptable risk by trial participation.
Subject is currently enrolled in an investigational drug, biologic, or device trial.
Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to Visit 2/Baseline.

Study & Design

Arm && Interventions

Group	Intervention	Description
ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.	ADX-629	-

Primary Outcome Measures

Name	Time	Method
Adverse Event Assessment	Safety Assessment Period (Day 1 - 85)	Adverse Event Collection

Secondary Outcome Measures

Name	Time	Method

Recruitment & Eligibility